{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:35:55Z","timestamp":1740123355293,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010881","name":"Suzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["SKYXD2022022"],"award-info":[{"award-number":["SKYXD2022022"]}],"id":[{"id":"10.13039\/501100010881","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzhou Pharmaceutical Association","award":["SKYXD2022022"],"award-info":[{"award-number":["SKYXD2022022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10637-024-01438-y","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T07:01:50Z","timestamp":1719298910000},"page":"418-427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study on the effects of rapamycin and the mTORC1\/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS\/MS metabolomics"],"prefix":"10.1007","volume":"42","author":[{"given":"Kai","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangyujing","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yewen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"1438_CR1","doi-asserted-by":"publisher","first-page":"e8242","DOI":"10.1097\/md.0000000000008242","volume":"96","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Chen Z, Li J (2017) The current status of treatment for colorectal cancer in China: a systematic review. Med (Baltim) 96:e8242. https:\/\/doi.org\/10.1097\/md.0000000000008242","journal-title":"Med (Baltim)"},{"key":"1438_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"issue":"10207","key":"1438_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet (London England) 394(10207):1467\u20131480. https:\/\/doi.org\/10.1016\/S0140-6736(19)32319-0","journal-title":"Lancet (London England)"},{"issue":"1","key":"1438_CR4","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41467-020-15795-8","volume":"11","author":"ML Weng","year":"2020","unstructured":"Weng ML, Chen WK, Chen XY, Lu H, Sun ZR, Yu Q, Sun PF, Xu YJ, Zhu MM, Jiang N, Zhang J, Zhang JP, Song YL, Ma D, Zhang XP, Miao CH (2020) Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT\/mTOR\/HIF1\u03b1 pathway suppression. Nat Commun 11(1):1869. https:\/\/doi.org\/10.1038\/s41467-020-15795-8","journal-title":"Nat Commun"},{"key":"1438_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A (2022) Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol 80:1\u201317. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.008","journal-title":"Semin Cancer Biol"},{"key":"1438_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471\u2013484. https:\/\/doi.org\/10.1016\/j.cell.2006.01.016","journal-title":"Cell"},{"key":"1438_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41417-019-0117-7","volume":"27","author":"H Wang","year":"2020","unstructured":"Wang H, Liu Y, Ding J, Huang Y, Liu J, Liu N, Ao Y, Hong Y, Wang L, Zhang L, Wang J, Zhang Y (2020) Targeting mTOR suppressed colon cancer growth through 4EBP1\/eIF4E\/PUMA pathway. Cancer Gene Ther 27:448\u2013460. https:\/\/doi.org\/10.1038\/s41417-019-0117-7","journal-title":"Cancer Gene Ther"},{"key":"1438_CR8","doi-asserted-by":"publisher","first-page":"655731","DOI":"10.3389\/fcell.2021.655731","volume":"9","author":"N Deleyto-Seldas","year":"2021","unstructured":"Deleyto-Seldas N, Efeyan A (2021) The mTOR-Autophagy Axis and the control of metabolism. Front Cell Dev Biol 9:655731. https:\/\/doi.org\/10.3389\/fcell.2021.655731","journal-title":"Front Cell Dev Biol"},{"key":"1438_CR9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell 169:361\u2013371. https:\/\/doi.org\/10.1016\/j.cell.2017.03.035","journal-title":"Cell"},{"key":"1438_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","volume":"12","author":"H Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y (2019) Targeting mTOR for cancer therapy. J Hematol Oncol 12:71. https:\/\/doi.org\/10.1186\/s13045-019-0754-1","journal-title":"J Hematol Oncol"},{"key":"1438_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/cr.2015.133","volume":"26","author":"Y Yin","year":"2016","unstructured":"Yin Y, Hua H, Li M, Liu S, Kong Q, Shao T, Wang J, Luo Y, Wang Q, Luo T, Jiang Y (2016) mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res 26:46\u201365. https:\/\/doi.org\/10.1038\/cr.2015.133","journal-title":"Cell Res"},{"key":"1438_CR12","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1530\/eje-13-0586","volume":"170","author":"B Verg\u00e8s","year":"2014","unstructured":"Verg\u00e8s B, Walter T, Cariou B (2014) Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 170:R43\u201355. https:\/\/doi.org\/10.1530\/eje-13-0586","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1438_CR13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","volume":"101","author":"A Szwed","year":"2021","unstructured":"Szwed A, Kim E, Jacinto E (2021) Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev 101(3):1371\u20131426. https:\/\/doi.org\/10.1152\/physrev.00026.2020","journal-title":"Physiol Rev"},{"issue":"16","key":"1438_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/onc.2016.363","volume":"36","author":"LC Kim","year":"2017","unstructured":"Kim LC, Cook RS, Chen J (2017) mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene 36(16):2191\u20132201. https:\/\/doi.org\/10.1038\/onc.2016.363","journal-title":"Oncogene"},{"key":"1438_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS, Kelly KR, Nawrocki ST (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6:17\u201327. https:\/\/doi.org\/10.1007\/s11523-011-0167-8","journal-title":"Target Oncol"},{"issue":"8","key":"1438_CR16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/cbin.11792","volume":"46","author":"J Lou","year":"2022","unstructured":"Lou J, Lv JX, Zhang YP, Liu ZJ (2022) OSI-027 inhibits the tumorigenesis of colon cancer through mediation of c-Myc\/FOXO3a\/PUMA axis. Cell Biol Int 46(8):1204\u20131214. https:\/\/doi.org\/10.1002\/cbin.11792","journal-title":"Cell Biol Int"},{"issue":"8","key":"1438_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","volume":"10","author":"SV Bhagwat","year":"2011","unstructured":"Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA (2011) Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 10(8):1394\u20131406. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-1099","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"1438_CR18","doi-asserted-by":"publisher","first-page":"12470","DOI":"10.3390\/ijms232012470","volume":"23","author":"O Afzal","year":"2022","unstructured":"Afzal O, Altamimi ASA, Mubeen B, Alzarea SI, Almalki WH, Al-Qahtani SD, Atiya EM, Al-Abbasi FA, Ali F, Ullah I, Nadeem MS, Kazmi I (2022) mTOR as a potential target for the Treatment of Microbial Infections, Inflammatory Bowel diseases, and Colorectal Cancer. Int J Mol Sci 23(20):12470. https:\/\/doi.org\/10.3390\/ijms232012470","journal-title":"Int J Mol Sci"},{"key":"1438_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ (2017) Understanding the intersections between Metabolism and Cancer Biology. Cell 168:657\u2013669. https:\/\/doi.org\/10.1016\/j.cell.2016.12.039","journal-title":"Cell"},{"key":"1438_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","volume":"31","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ (2017) A Pan-cancer Proteogenomic Atlas of PI3K\/AKT\/mTOR pathway alterations. Cancer Cell 31:820\u2013832e823. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.013","journal-title":"Cancer Cell"},{"issue":"18","key":"1438_CR21","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.1074\/jbc.M900573200","volume":"284","author":"IG Ganley","year":"2009","unstructured":"Ganley IG, Lam duH, Wang J, Ding X, Chen S, Jiang X (2009) ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 284(18):12297\u201312305. https:\/\/doi.org\/10.1074\/jbc.M900573200","journal-title":"J Biol Chem"},{"key":"1438_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.03.005","volume":"45","author":"F Massari","year":"2016","unstructured":"Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R (2016) Metabolic phenotype of bladder cancer. Cancer Treat Rev 45:46\u201357. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.005","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1438_CR23","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/cancers12051298","volume":"12","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Denk S, Wiegering A (2020) Targeting protein synthesis in Colorectal Cancer. Cancers 12(5):1298. https:\/\/doi.org\/10.3390\/cancers12051298","journal-title":"Cancers"},{"key":"1438_CR24","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2:e1600200. https:\/\/doi.org\/10.1126\/sciadv.1600200","journal-title":"Sci Adv"},{"key":"1438_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1126\/science.1193494","volume":"330","author":"AJ Levine","year":"2010","unstructured":"Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340\u20131344. https:\/\/doi.org\/10.1126\/science.1193494","journal-title":"Science"},{"key":"1438_CR26","doi-asserted-by":"publisher","first-page":"188559","DOI":"10.1016\/j.bbcan.2021.188559","volume":"1876","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, Balan M, Sabarwal A, Choueiri TK, Pal S (2021) Metabolic reprogramming in renal cancer: events of a metabolic disease. Biochim Biophys Acta Rev Cancer 1876:188559. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188559","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1438_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB (2022) The hallmarks of cancer metabolism: still emerging. Cell Metab 34:355\u2013377. https:\/\/doi.org\/10.1016\/j.cmet.2022.01.007","journal-title":"Cell Metab"},{"key":"1438_CR28","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/jcmm.16155","volume":"25","author":"S Li","year":"2021","unstructured":"Li S, Sheng J, Liu Z, Fan Y, Zhang C, Lv T, Hu S, Jin J, Yu W, Song Y (2021) Potent antitumour of the mTORC1\/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells. J Cell Mol Med 25:2436\u20132449. https:\/\/doi.org\/10.1111\/jcmm.16155","journal-title":"J Cell Mol Med"},{"key":"1438_CR29","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1158\/1078-0432.Ccr-18-2548","volume":"25","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Zhang Y, Chen Y, Qian J, Zhang X, Yu K (2019) A novel mTORC1\/2 inhibitor (MTI-31) inhibits Tumor Growth, Epithelial-Mesenchymal Transition, metastases, and improves Antitumor Immunity in Preclinical models of Lung Cancer. Clin Cancer Res 25:3630\u20133642. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2548","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1438_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40170-022-00286-9","volume":"10","author":"C Marx","year":"2022","unstructured":"Marx C, Sonnemann J, Maddocks ODK, Marx-Bl\u00fcmel L, Beyer M, Hoelzer D, Thierbach R, Maletzki C, Linnebacher M, Heinzel T, Kr\u00e4mer OH (2022) Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress. Cancer Metabolism 10(1):10. https:\/\/doi.org\/10.1186\/s40170-022-00286-9","journal-title":"Cancer Metabolism"},{"key":"1438_CR31","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1172\/jci69741","volume":"123","author":"JR Doherty","year":"2013","unstructured":"Doherty JR, Cleveland JL (2013) Targeting lactate metabolism for cancer therapeutics. J Clin Invest 123:3685\u20133692. https:\/\/doi.org\/10.1172\/jci69741","journal-title":"J Clin Invest"},{"key":"1438_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.tcb.2013.11.008","volume":"24","author":"E Mills","year":"2014","unstructured":"Mills E, O\u2019Neill LA (2014) Succinate: a metabolic signal in inflammation. Trends Cell Biol 24:313\u2013320. https:\/\/doi.org\/10.1016\/j.tcb.2013.11.008","journal-title":"Trends Cell Biol"},{"key":"1438_CR33","doi-asserted-by":"publisher","unstructured":"Liu C, Ji L, Hu J, Zhao Y, Johnston LJ, Zhang X, Ma X (2021) Functional amino acids and autophagy: Diverse Signal Transduction and Application. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms222111427","DOI":"10.3390\/ijms222111427"},{"key":"1438_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41416-019-0620-5","volume":"122","author":"L Vettore","year":"2020","unstructured":"Vettore L, Westbrook RL, Tennant DA (2020) New aspects of amino acid metabolism in cancer. Br J Cancer 122:150\u2013156. https:\/\/doi.org\/10.1038\/s41416-019-0620-5","journal-title":"Br J Cancer"},{"key":"1438_CR35","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41388-020-01480-z","volume":"39","author":"H Peng","year":"2020","unstructured":"Peng H, Wang Y, Luo W (2020) Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene 39:6747\u20136756. https:\/\/doi.org\/10.1038\/s41388-020-01480-z","journal-title":"Oncogene"},{"key":"1438_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cns.13610","volume":"27","author":"V Castelli","year":"2021","unstructured":"Castelli V, Paladini A, d\u2019Angelo M, Allegretti M, Mantelli F, Brandolini L, Cocchiaro P, Cimini A, Varrassi G (2021) Taurine and oxidative stress in retinal health and disease. CNS Neurosci Ther 27:403\u2013412. https:\/\/doi.org\/10.1111\/cns.13610","journal-title":"CNS Neurosci Ther"},{"key":"1438_CR37","doi-asserted-by":"publisher","unstructured":"Baliou S, Adamaki M, Ioannou P, Pappa A, Panayiotidis MI, Spandidos DA, Christodoulou I, Kyriakopoulos AM, Zoumpourlis V (2021) Protective role of taurine against oxidative stress (review). Mol Med Rep 24. https:\/\/doi.org\/10.3892\/mmr.2021.12242","DOI":"10.3892\/mmr.2021.12242"},{"key":"1438_CR38","doi-asserted-by":"publisher","first-page":"174361","DOI":"10.1016\/j.ejphar.2021.174361","volume":"908","author":"A Bhattacharjee","year":"2021","unstructured":"Bhattacharjee A, Prajapati SK, Krishnamurthy S (2021) Supplementation of taurine improves ionic homeostasis and mitochondrial function in the rats exhibiting post-traumatic stress disorder-like symptoms. Eur J Pharmacol 908:174361. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174361","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1438_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2012.09.019","volume":"215","author":"Y Li","year":"2012","unstructured":"Li Y, Hu Z, Chen B, Bu Q, Lu W, Deng Y, Zhu R, Shao X, Hou J, Zhao J, Li H, Zhang B, Huang Y, Lv L, Zhao Y, Cen X (2012) Taurine attenuates methamphetamine-induced autophagy and apoptosis in PC12 cells through mTOR signaling pathway. Toxicol Lett 215(1):1\u20137. https:\/\/doi.org\/10.1016\/j.toxlet.2012.09.019","journal-title":"Toxicol Lett"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01438-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01438-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01438-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:06:27Z","timestamp":1723716387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01438-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01438-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"9 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}